COVID variant JN.1 listed as ‘variant of interest’ by World Health Organization

In a recent development, the World Health Organization (WHO) has designated the COVID-19 variant known as JN.1 as a "variant of interest." Previously grouped under its parent strain, BA.2.86, JN.1 garnered attention due to its numerous mutations. Importantly, there is no evidence to suggest that JN.1 leads to more severe illness, and existing tests, vaccines, and treatments remain effective against it.

Currently, JN.1 accounts for approximately 21% of new COVID cases in the United States, with the Northeast region experiencing the highest proportion of infections at around 32%. Despite its increased presence, the WHO assesses the public health risk associated with JN.1 as low. However, as the holiday season approaches and people gather, experts advise continued caution to curb transmission rates and minimize the potential impact of this variant.

While JN.1's classification as a "variant of interest" warrants monitoring, the reassuring news is that current public health measures, including testing, vaccination, and treatment protocols, are still applicable and effective in managing its spread.